The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Evaluating worldwide disparities in bladder cancer clinical trial availability.
 
Koral Shah
No Relationships to Disclose
 
Daniela Castro
No Relationships to Disclose
 
Xiaochen Li
No Relationships to Disclose
 
Miguel Zugman
No Relationships to Disclose
 
Jalen Patel
No Relationships to Disclose
 
Teebro Paul
No Relationships to Disclose
 
Jaya Goud
No Relationships to Disclose
 
Samuel Dickter
No Relationships to Disclose
 
Lea Dickter
No Relationships to Disclose
 
Ishaan Bhatnagar
No Relationships to Disclose
 
Salvador Jaime-Casas
No Relationships to Disclose
 
Hedyeh Ebrahimi
No Relationships to Disclose
 
Benjamin Mercier
No Relationships to Disclose
 
Joann Hsu
No Relationships to Disclose
 
Nazli Dizman
Stock and Other Ownership Interests - Several pharmaceutical companies (I)
Consulting or Advisory Role - Vivreon Biosciences
 
Alex Chehrazi-Raffle
Honoraria - ASCO; EPG Health; Medical Oncology Association of Southern California; OncLive/MJH Life Sciences
Consulting or Advisory Role - Aveo Inc; Eisai; Exelixis; Seagen
Speakers' Bureau - Exelixis
Research Funding - Exelixis
Travel, Accommodations, Expenses - Bayer
 
Abhishek Tripathi
Consulting or Advisory Role - AADi; Bayer; Deka biosciences; Exelixis; Gilead Sciences; Pfizer; Seattle Genetics/Astellas
Speakers' Bureau - Sanofi
 
Regina Barragan-Carrillo
No Relationships to Disclose
 
Sumanta Pal
Speakers' Bureau - IntrinsiQ; MJH Life Sciences; Peerview
Travel, Accommodations, Expenses - crispr therapeutics; Exelixis; Ipsen